The board did not print a new approval or CRL last week, but it did need one correction. IRWD / LINZESS® belongs on the live board with a May 24 PDUFA for functional constipation in children ages 2–5. That makes Ironwood the next real FDA clock, ahead of MNKD, CING, AZN, SPRO, ACHV, and ARQT.
The immediate question is no longer whether there was a fresh event to chase last week. There was not. The job now is cleaner: reset the board, add the missed May 24 date, and move into a denser late-May / June PDUFA stack.
|
+
|
IRWD / LINZESS® — ADDED TO BOARD · PDUFA May 24
This was not on last week’s forward board, but it should be. LINZESS is under review for functional constipation in patients ages 2–5, with a May 24 PDUFA date and a 65% PoA in the current data.
|
|
··
|
BIIB / LEQEMBI IQLIK — REMAINS OFF BOARD · New date Aug 24
No change here. BIIB remains out of the near-term window after the FDA extended the LEQEMBI IQLIK review to August 24 following a request for additional information classified as a major amendment.
|
| PDUFA | Window | Ticker | Event | PoA |
| Sun May 24 | Fri 22 / Tue 26 | IRWD | LINZESS® / FC, ages 2–5 | 65% |
| Fri May 29 | Fri May 29 | MNKD | Afrezza / peds T1D & T2D, ages 4–17 | 72% |
| Sun May 31 | Fri 29 / Mon Jun 1 | CING | CTx-1301 / ADHD | 75% |
| Tue Jun 2 | Tue Jun 2 | AZN | DATROWAY® / 1L mTNBC, IO-ineligible | 86% |
| Thu Jun 18 | Thu Jun 18 | SPRO | tebipenem HBr / cUTI, incl. pyelo | 92.5% |
| Sat Jun 20 | Thu 18 / Mon 22 | ACHV | cytisinicline / smoking cessation | 82% |
| Mon Jun 29 | Mon Jun 29 | ARQT | ZORYVE® cream / psoriasis, ages 2–5 | 95%+ |
| IRWD $IRWD · LINZESS® · FC ages 2–5 | PDUFA: Sun May 24 PoA 65% |
This is now the next real hard clock. The setup is a pediatric label expansion for an already established GI franchise, but the age group matters. LINZESS is already approved in older pediatric populations, while the current review pushes into children ages 2–5, where safety sensitivity is higher and the boxed warning against use under age 2 keeps the risk conversation alive.
| MNKD $MNKD · Afrezza · peds T1D & T2D | PDUFA: Fri May 29 PoA 72% |
A pediatric label expansion for an already approved inhaled insulin product. The commercial hook is obvious: needle-free mealtime insulin for children and adolescents ages 4–17 with type 1 or type 2 diabetes. The regulatory risk is also specific: INHALE-1 missed HbA1c noninferiority on the full ITT analysis, while MannKind’s defense leans on a modified analysis excluding one nonadherent patient. The FDA decision likely turns on whether reviewers accept that sensitivity case alongside stable pulmonary function, patient satisfaction, and weight effects.
| CING $CING · CTx-1301 · ADHD | PDUFA: Sun May 31 PoA 75% |
A 505(b)(2) ADHD setup with a live FDA date at month-end. The story is straightforward: known active ingredient, differentiated timed-release platform, and an attempt to carve out a full-day symptom-control position in a crowded stimulant market. The cash position is less of a near-term issue after the Q1 update; the more relevant FDA nuance is manufacturing and CMC, where the company has said it is responding to agency information requests.
| AZN $AZN · DATROWAY® · 1L mTNBC, IO-ineligible | PDUFA: Tue Jun 2 PoA 86% |
Large-cap, Priority Review, and a real early-June FDA decision. The sBLA is for adult patients with unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy — the defining feature of this setup.
| SPRO $SPRO · tebipenem HBr · cUTI, incl. pyelo | PDUFA: Thu Jun 18 PoA 92.5% |
This now belongs on the board. The setup is unusually clean for a smaller-cap name because the asset is partnered with GSK and the core pitch is simple: a potential first oral carbapenem option for complicated urinary tract infections, including pyelonephritis.
| ACHV $ACHV · cytisinicline · smoking cessation | PDUFA: Sat Jun 20 PoA 82% |
A later-June NDA with a public-health angle and two Phase 3 smoking-cessation studies behind it. The separate vaping-cessation program also received the FDA Commissioner’s National Priority Voucher, which does not decide the smoking-cessation NDA but does add a useful regulatory-tailwind signal around the broader cytisinicline franchise.
| ARQT $ARQT · ZORYVE® 0.3% · plaque psoriasis, ages 2–5 | PDUFA: Mon Jun 29 PoA 95%+ |
A pediatric label expansion around an already approved and commercialized dermatology franchise. The capped PoA reflects a heavily de-risked label-expansion setup, not a guarantee.
The board does not rotate by result this week. It rotates by correction.
IRWD is added as the next hard clock. BIIB stays off after the August extension. SPRO moves into the forward window. The next real work shifts to:
| IRWD | → | MNKD | → | CING | → | AZN |
| SPRO | → | ACHV | → | ARQT |
That is the queue.
Informational only · Not investment advice · Biotech carries risk of total loss